Who are Exenatide once weekly (EQW )'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mounjaro, Ozempic, Trulicity, Albugon, Byetta, Byetta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/exenatide-once-weekly-eqw.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Exenatide once weekly (EQW ) — Competitive Intelligence Brief

Exenatide once weekly (EQW ) (Exenatide once weekly (EQW )) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Diabetes.

phase 3 GLP-1 receptor agonist GLP-1R (GLP-1 receptor) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Exenatide once weekly (EQW ) (Exenatide once weekly (EQW )) — Woman's. Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion in response to elevated blood glucose and slows gastric emptying to reduce postprandial glucose levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Exenatide once weekly (EQW ) TARGET	Exenatide once weekly (EQW )	Woman's	phase 3	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)
Mounjaro	TIRZEPATIDE	Eli Lilly	marketed	Dual GIP/GLP-1 receptor agonist	GIP receptor and GLP-1 receptor	2022-01-01
Ozempic	semaglutide	Novo Nordisk	marketed	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2017-01-01
Trulicity	DULAGLUTIDE	Eli Lilly	marketed	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2014-01-01
Albugon	ALBIGLUTIDE	GSK	marketed	GLP-1 Receptor Agonist	Glucagon-like peptide 1 receptor	2014-01-01
Byetta	Byetta	AstraZeneca	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Byetta	EXENATIDE	AstraZeneca	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-17 — Ozempic · 11097063 · US
2026-07-17 — Ozempic · 8920383 · US
2026-07-17 — Ozempic · 9775953 · US
2026-07-17 — Ozempic · 10220155 · US
2026-08-03 — Ozempic · RE46363 · US
2026-08-18 — Byetta · 9884092 · US
2026-08-18 — Byetta · 8906851 · US
2026-08-18 — Byetta · 8329648 · US
2027-02-18 — Byetta · 8329648*PED · US
2027-02-18 — Byetta · 8906851*PED · US
2027-02-18 — Byetta · 9884092*PED · US
2027-02-27 — Ozempic · 9687611 · US
2027-06-20 — Byetta · 8501698 · US
2027-09-27 — Ozempic · 9457154 · US
2027-11-12 — Byetta · 8758292 · US
2027-12-20 — Byetta · 8501698*PED · US
2028-01-12 — Byetta · 8216180 · US
2028-03-21 — Byetta · 8361972 · US
2028-03-25 — Byetta · 9320853 · US
2028-03-25 — Byetta · 8439864 · US
2028-05-12 — Byetta · 8758292*PED · US
2028-07-12 — Byetta · 8216180*PED · US
2028-09-21 — Byetta · 8361972*PED · US
2028-09-25 — Byetta · 8439864*PED · US
2028-09-25 — Byetta · 9320853*PED · US
2029-02-04 — Byetta · 8827963 · US
2029-05-19 — Byetta · 8690837 · US
2029-08-04 — Byetta · 8827963*PED · US
2029-11-19 — Byetta · 8690837*PED · US
2030-01-07 — Byetta · 8998876 · US

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Exenatide once weekly (EQW ) — Competitive Intelligence Brief. https://druglandscape.com/ci/exenatide-once-weekly-eqw. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab